Oncology Business Management

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.

The novel PLK1 inhibitor volasertib in combination with low-dose cytarabine has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with untreated AML.

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor (EGFR) mutation.

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

The federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors' offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of ASCO.

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

A hot topic of discussion at the American Society of Clinical Oncology (ASCO) meeting in June was the Patient Protection and Affordable Care Act (often referred to as the ACA) and what it means for the future of oncology care in the United States.

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

The FDA has given priority review designation to sorafenib for the treatment of locally advanced or metastatic RAI-refractory differentiated thyroid cancer.

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

The oncology pipeline is crowded, despite the fact that the agents in development target a broad range of tumor types.

Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement.